関連する実験動画
Updated: Jul 14, 2026

05:52
Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
マスト細胞の安定化は,実験的な不全性脳卒中における血栓抑制薬の投与後の出血形成と死亡率を減少させます
Daniel Strbian1, Marja-Liisa Karjalainen-Lindsberg, Petri T Kovanen
1Department of Neurology, Helsinki University Central Hospital, Haartmaninkatu 8, 00290 Helsinki, Finland.
Circulation
|July 4, 2007
まとめ
脳卒中に対する組織プラズミノゲン活性化剤 (tPA) 治療後の出血と損傷には,脳のマスト細胞 (MCs) が寄与する. MCを安定させることで,これらの有害な影響が軽減され,結果と生存率が改善されました.
科学分野:
- 神経科学は神経科学である.
- 免疫学 免疫学とは
- 血管生物学 血管生物学
背景:
- 組織プラズミノゲン活性化剤 (tPA) は脳卒中治療に不可欠ですが,出血合併症や再注射損傷を引き起こす可能性があります.
- 脳のマスト細胞 (MCs) は,脱粒化時に血管活性物質とタンパク質分解物質を放出し,脳卒中に関連する損傷を悪化させる可能性があります.
- 以前の研究によると,MCsは,不血性および出血性脳腫と中性粒子の蓄積を増加させる.
研究 の 目的:
- 組織プラズミノゲン活性化剤 (tPA) 媒介の出血形成 (HF) と再注射傷害におけるマスト細胞 (MCs) の役割を調査する.
- tPA誘発の合併症を緩和するマスト細胞安定化の治療的可能性を評価する.
主な方法:
- 脱粒化を評価するために,tPAに対するMCのインビトロ暴露.
- ネズミにおけるインビオ焦点性脳缺血/再注射モデル.
- クロモグリケートを用いた薬理学的MC安定化.
- MC欠乏したラットの評価.
- 出血形成,脳腫れ,中性粒子の浸透,神経学的結果,および死亡率の評価.
主要な成果:
- 実験室でのtPA暴露は,MCの有意なデグラニュレーションを誘発した.
- ネズミに発血後のtPA投与は,出血形成の70〜100倍の増加をもたらしました.
- クロモグリケートによるMC安定化は,tPA媒介のHFを24時間後に96%大幅に減少させた.
- MC欠乏のラットは24時間後にtPA媒介のHFの有意な減少 (89%) を示した.
- MCの安定化と欠乏の両方が,脳の腫れ,中性粒子の浸透を軽減し,神経学的結果と生存を改善しました.
結論:
- マスト細胞は,tPA投与後の出血形成と再注射損傷において重要な役割を果たします.
- マスト細胞の薬理学的安定化は,血栓解消療法の安全性を高める有望な治療戦略です.
- マスト細胞をターゲットにすることで,tPAによる脳卒中治療後の患者の予後を改善することができる.
関連する概念動画
Vascular Spasm
The vascular phase, also known as vasospasm, is the initial stage of hemostasis, crucial for preventing excessive bleeding when a blood vessel is injured. After a vessel is cut, nerves in the damaged area trigger pain and other sensory impulses. Simultaneously, the smooth muscles in the vessel wall contract, resulting in a vascular spasm. This contraction reduces the vessel's diameter at the injury site, slowing or stopping blood loss through the vessel wall. Vascular spasms typically last for...
Introduction to Hemostasis
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Hemorrhagic Stroke ll: Pathophysiology
A hemorrhagic stroke develops when a cerebral blood vessel ruptures, allowing blood to escape into the surrounding brain tissue, as in intracerebral hemorrhage (ICH), or into the subarachnoid space, as in subarachnoid hemorrhage (SAH). Because the skull is a rigid compartment, the sudden presence of extravascular blood rapidly increases intracranial pressure and compresses adjacent neural structures, leading to immediate tissue injury and impaired cerebral perfusion.Mass Effect and Primary...

